Event Type
Disclosure
Voluntary
Variant
8-K
Regulation FD Disclosure On February 25, 2026, Tempest Therapeutics, Inc. (the “Company”) posted an updated corporate presentation, dated February 25, 2026, to
Other Events On February 25, 2026, the Company issued a press release entitled “Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Prep
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release, dated February 25, 2026 104 Cover Page Interactive Data File (embedd